

10/798,161

KEM  
2/5/07

Page 3 of 3

K6	55	EP 0491803 B1	7-20-99	EP				
	56	FR 2776191	9-24-99	France (with abstract)			X	
	57	EP 0804926 B1	10-27-99	EP				
	58	EP 0655900 B1	3-15-00	EP				
	59	EP 0719538 B1	11-8-00	EP				
	60	EP 0814776 B1	7-4-01	EP (with abstract)			X	
	61	EP 0643963 B1	11-14-01	EP				
	62	EP 0868187 B1	12-5-01	EP				
	63	EP 0859793 B1	2-13-02	EP				
	64	EP 1089722 B1	5-22-02	EP				
K6	65	EP 0802782 B1	2-5-03	EP				
67 FOREIGN PUBLISHED PATENT APPLICATIONS								
K6	66	WO 92/08730	5-29-92	Laboratoire Theramax SAM Assignee				
	67	WO 94/06437	3-31-94	Laboratoire Theramax SAM Assignee				
	68	JP 09176049	7-8-97	Suzuki et al. (with abstract)			X	
	69	WO 97/03676	2-6-97	Cabo et al. (with abstract)			X	
	70	WO 97/34607	9-27-97	Ludwig				
	71	WO 98/37879	9-3-98	Hsieh				
	72	WO 99/24041	5-20-99	Cellegy Pharmaceuticals, Inc.				
	73	WO 99/48477	9-30-99	Laboratoire Theramax SAM Assignee (with abstract)			X	
	74	WO 99/20257	4-29-01	Beier et al.				
K6	75	WO 02/22132	2-21-02	Laboratoire Theramax SAM Assignee (with abstract)			X	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
EXAMINER KEM				DATE CONSIDERED 12/6/05				
*EXAMINE R: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								